# EDGAR Filing Document

**Accession Number:** 0001324991
**File Stem:** 0001209191-23-004931
**Filing Date:** 2023-1
**Character Count:** 8315
**Document Hash:** 0d952ba91decb7c4c82853ad90a3715b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-004931.hdr.sgml**: 20230125

**ACCESSION NUMBER**: 0001209191-23-004931

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230125

**FILED AS OF DATE**: 20230125

**DATE AS OF CHANGE**: 20230125

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Tyree James L
- **CENTRAL INDEX KEY:** 0001324991

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41599
- **FILM NUMBER:** 23553644

**MAIL ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-6400
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GENELUX CORP
- **CENTRAL INDEX KEY:** 0001231457
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1177 IDAHO STREET
- **CITY:** REDLANDS
- **STATE:** CA
- **ZIP:** 92374
- **BUSINESS PHONE:** 858-483-0024

**MAIL ADDRESS:**
- **STREET 1:** 1177 IDAHO STREET
- **CITY:** REDLANDS
- **STATE:** CA
- **ZIP:** 92374

## Ex-24

```

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints
each of Thomas Zindrick, J.D., and Sean Ryder, J.D., of Genelux Corporation (the
"Company"), signing individually, the undersigned's true and lawful
attorney-in-fact and agent to:

(1) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of the Company, Forms 3, 4
and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act") and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and

(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that each of the foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, is not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact
shall no longer be employed by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 5th day of July, 2022.

/s/ James L. Tyree

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Tyree James L<br><sub>(Last) (First) (Middle)</sub><br>C/O GENELUX CORPORATION<br>2625 TOWNSGATE ROAD, SUITE 230<br><sub>(Street)</sub><br>WESTLAKE VILLAGE, CA 91361<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>GENELUX CORP [ GNLX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-01-25 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | <sup>(1)</sup> | 2024-06-26 | Common Stock | 25000 | $9.00 | D |  |
| Stock Option (right to buy) | <sup>(1)</sup> | 2024-06-26 | Common Stock | 25000 | $9.00 | I | By spouse |
| Stock Option (right to buy) | <sup>(1)</sup> | 2026-03-16 | Common Stock | 2500 | $9.00 | D |  |
| Stock Option (right to buy) | <sup>(1)</sup> | 2026-03-16 | Common Stock | 2500 | $9.00 | I | By spuse |
| Stock Option (right to buy) | <sup>(1)</sup> | 2026-12-30 | Common Stock | 2500 | $9.00 | D |  |
| Stock Option (right to buy) | <sup>(1)</sup> | 2026-12-30 | Common Stock | 2500 | $9.00 | I | By spouse |
| Stock Option (right to buy) | <sup>(1)</sup> | 2028-05-22 | Common Stock | 2500 | $10.50 | D |  |
| Stock Option (right to buy) | <sup>(1)</sup> | 2028-05-22 | Common Stock | 2500 | $10.50 | I | By spouse |
| Stock Option (right to buy) | <sup>(1)</sup> | 2028-12-30 | Common Stock | 14000 | $10.50 | D |  |
| Stock Option (right to buy) | <sup>(1)</sup> | 2029-12-30 | Common Stock | 14250 | $10.50 | D |  |
| Stock Option (right to buy_ | <sup>(1)</sup> | 2030-09-23 | Common Stock | 15675 | $10.50 | D |  |
| Stock Option (right to buy) | <sup>(1)</sup> | 2030-09-23 | Common Stock | 17642 | $10.50 | D |  |
| Stock Option (right to buy) | <sup>(1)</sup> | 2032-09-08 | Common Stock | 25000 | $10.50 | D |  |

---

### Footnotes:

(1) Immediately exercisable.

**Signature:** /s/ Sean Ryder, J.D., Attorney-in-Fact  
**Date:** 2023-01-25

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**